Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically slashes current time-consuming DNA amplification from hours to minutes.
Strong demand predicted across all life science markets
Amsterdam, December 1, 2017: Dutch biotechnology company Molecular Biology Systems (MBS) today announced it will launch its revolutionary NEXTGENPCR thermal cycler through AMPLITECH, an independent commercial organization offering innovative solutions to the public and private in vitro diagnostic testing market, including cytogenetics, molecular genetics, and pathology labs, in France, Belgium, Luxembourg, and Switzerland.
The growth potential of the French and Swiss markets for molecular biology tests is considerable, with significant investments being made to develop new molecular diagnostic testing capabilities in all sectors of the life sciences (health, academic research, R & D, agro-food, biotechnologies ...). Susane Darchis, President and CEO of Amplitech, said, " “We believe that NEXTGENPCR is an excellent strategic fit for Amplitech to increase the commercial potential of our PCR-based test ranges, as well as to approach the increasing number of labs facing demands for accelerated results. “
Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically slashes current time-consuming DNA amplification from hours to minutes. For example, a 3 Step, 30 cycle protocol can be performed in less than 2 minutes. SBS Standard format 96- or 384 well microplates are used, making incorporation into existing laboratory routines and protocols seamless. NEXTGENPCR delivers these astonishing times by turning existing technology on its head. Instead of heating and cooling Peltier blocks, NEXTGENPCR cleverly moves standard format microplates rapidly across 3 temperature zones already set to the required denaturing, extension and annealing temperatures. The microplate samples are embedded in polypropylene sheet and slightly compressed by the temperature blocks in each zone which ensures thorough sample mixing and optimal heat transfer. Well to well uniformity across the block is better than 0.1 °C. Temperature transition is practically instantaneous with a total reaction time of 2 minutes. This results in a dramatic reduction in power consumption when compared to traditional heating block methods.
Established for over 20 years, AMPLITECH has built a strong reputation in the life sciences and in vitro diagnostic markets, and is well known among the medical genetic community, including prenatal, postnatal, hemato-oncology, and oncology labs. ”AMPLITECH is dedicated to providing innovative solutions for all the growing number of newly identified laboratory needs in the in vitro molecular diagnostic market. That’s why we are delighted to be able to offer NEXTGENPCR. There is a real customer need to speed up the thermal cycling phase and bring faster diagnostic results to the patients,” says Susane Darchis, AMPLITECH’s General Manager & Founder. “We will launch NEXTGENPCR at next Assises de Génétique Humaine et Médicale in Nantes France (January 24-26, 2018) and are expecting strong interest. "
“We are also delighted to have signed this agreement with such a reputable distributor in the key French and Swiss markets,” says MBS CEO and founder Gert de Vos. “NEXTGENPCR’s ability to slash amplification times from hours to minutes and fit seamlessly into any lab routines and protocols is proving a major success factor. Our global network is now close to completion with further announcements due shortly.”
For further information: Gert de Vos, CEO gertdevos@mbspcr.com www.nextgenpcr.com
Media:
Richard Hayhurst
